ArticleOphthalmology science
Risk of Systemic Health Events and Mortality After Vitrectomy for Diabetic Retinopathy in Patients with Type 2 Diabetes.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To quantify the risk of mortality, myocardial infarction (MI), stroke, and amputation in patients with type 2 diabetes mellitus (T2DM) who underwent pars plana vitrectomy (PPV) for diabetic retinopathy (DR) compared with those not requiring PPV. Design: A retrospective cohort study utilizing the TriNetX US Collaborative Network. Subjects: The study included 9081 patients with T2DM who underwent PPV for DR, 363 116 patients with T2DM with DR but no PPV, 92 645 patients with T2DM without DR, and 3 264 709 healthy individuals, all aged ≥18 years. Methods: We identified cohorts using specific International Classification of Diseases, 10th Revision and Current Procedural Technology codes. We used propensity score matching to adjust for covariates including age, gender, race, ethnicity, systemic pathology, and ocular conditions unrelated to diabetes. Main Outcome Measures: The primary outcome measures were the hazard ratios (HRs) for mortality, MI, stroke, and amputation at 1, 3, and 5 years after PPV compared with the control groups. Results: Patients with T2DM undergoing PPV for DR had higher risk of systemic events and mortality. Compared with patients with DR not requiring PPV, the PPV cohort had a higher risk at 1 year for stroke (HR: 1.51; 95% confidence interval [CI]: 1.03, 2.21) and amputation (HR: 1.85; 95% CI: 1.08, 3.16). At 3 years, the risks for MI (HR: 1.44; 95% CI: 1.17, 1.78), stroke (HR: 1.61; 95% CI: 1.25, 2.07), and amputation (HR: 2.17; 95% CI: 1.54, 3.05) were significantly elevated. At 5 years, the risks for mortality (HR: 1.28; 95% CI: 1.13, 1.43), MI (HR: 1.50; 95% CI: 1.26, 1.78), stroke (HR: 1.54; 95% CI: 1.25, 1.91), and amputation (HR: 2.10; 95% CI: 1.58, 2.81) were all significantly higher. When compared with diabetic patients without DR or healthy patients, the PPV cohort faced higher risk of each health outcome analyzed at intervals of 1, 3, and 5 years. Conclusions: We found a significant association between patients with T2DM with DR requiring PPV and an increased risk of mortality, MI, stroke, and amputation compared with non-PPV patients with DR, diabetics without DR, and healthy individuals. These findings underscore the need for monitoring and management of systemic health in diabetic patients undergoing PPV for advanced DR. Financial Disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.